CSIMarket
 
Alterity Therapeutics Limited  (ATHE)
Other Ticker:  
 
 
Price: $1.8000 $0.04 2.273%
Day's High: $1.87 Week Perf: 8.43 %
Day's Low: $ 1.79 30 Day Perf: -9.09 %
Volume (M): 11 52 Wk High: $ 5.41
Volume (M$): $ 20 52 Wk Avg: $2.54
Open: $1.87 52 Wk Low: $1.55



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 35
 Capital Exp. (TTM) (Millions $) 0

Alterity Therapeutics Limited
Alterity Therapeutics Limited is a biotechnology company that focuses on developing innovative therapeutics for neurodegenerative diseases. The company's primary focus is on Parkinson's disease and other related disorders, such as Multiple System Atrophy and Alzheimer's disease.

Alterity Therapeutics is known for their unique approach to drug development, which involves targeting the abnormal accumulation of iron in the brain. Their lead drug candidate, PBT434, has shown promising results in preclinical studies and is currently being evaluated in clinical trials for Parkinson's disease.

The company is dedicated to advancing the understanding of neurodegenerative diseases and improving the lives of patients through the development of safe and effective treatments. Alterity Therapeutics collaborates with leading academic institutions and research organizations to accelerate their drug discovery and development programs.

Alterity Therapeutics Limited is headquartered in Melbourne, Australia, and is listed on the Australian Securities Exchange (ASX: ATH).


   Company Address: Level 14, 350 Collins Street Melbourne 3000
   Company Phone Number: 3 9349 4906   Stock Exchange / Ticker: NASDAQ ATHE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Alterity Therapeutics Phase 2 Clinical Trial ACCELERATE Shows Promising Continuation Based on DMC Review

Published Tue, Feb 6 2024 12:25 PM UTC

The pharmaceutical industry is constantly striving to develop novel therapeutic interventions for various diseases, particularly those with significant unmet medical needs. Alterity Therapeutics is one such company dedicated to advancing groundbreaking treatments, with their latest phase 2 clinical trial of ATH434-201 showing considerable promise. In this article, we will de...

Management Announcement

Alterity Therapeutics: Pioneering New Frontiers in Neurodegenerative Disease Treatment

Published Mon, Jan 22 2024 12:25 PM UTC



In a recent shareholder letter, Alterity Therapeutics highlighted significant advancements in their pipeline, sharing updates on key upcoming milestones. The company has also generated preliminary data from the ATH434-202 Study, with expectations for the completion of the ATH434-201 Study in November 2024. These developments hold immense potential for the future pr...

Clinical Study

Alterity Therapeutics' Unveils Game-Changing Biomarkers for Multiple System Atrophy, Paving the Way for Transformative Treatments

Published Mon, Nov 27 2023 12:25 PM UTC



Alterity Therapeutics, a prominent biotechnology company focused on developing transformative therapies for neurodegenerative disorders, has announced a significant breakthrough in the evaluation of Multiple System Atrophy (MSA). The company recently presented novel biomarker data from its Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural Histo...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com